



General Insurance >

Result Update >

April 29, 2025

CMP (Rs): 309 | TP (Rs): 250

Go Digit's Q4FY25 results were a mixed bag. Amid the volatile and difficult external environment in FY25, marked by EoM glidepath, no Motor TP tariff hike, sustained competition in Motor OD, and implementation of 1/n regulations for gross premium accounting, the company found it difficult to replicate its past success of accelerating growth with improving profitability (Read our initiation: Just another brick in the wall). Looking ahead, we continue to see challenges in the company's journey to deliver superior growth with improving profitability, as i) no Motor TP tariff hike in FY26 (Read: Brace for an unchanged Motor TP tariff in FY26) and lower support from past reserves; ii) EoM compliance by Mar-26 to drive price competition in the group health business; iii) a few large profitable corporate and group Health/PA policies of the company to see price negotiations; iv) falling bond yields pose reinvestment risks. To reflect the Q4FY25 results and outlook, we change our estimates for FY26-27 which leads to broadly unchanged CoR and increase in PAT by ~3-8%. We reiterate SELL with unchanged Mar-26E TP of Rs250 (implying FY27 P/E of 34x).

### Q4FY25 results a mixed bag

Go Digit posted mixed result during Q4FY25, with GWP at Rs25.8bn (+10.3% YoY), largely in line with our estimates; though PAT at Rs1.16bn was 6% above our estimates despite the higher-than-estimated Combined Ratio at 111.3%. The PAT beat was driven by ~9% beat on NEP, while investment income was ~3% higher than our estimate. CoR during Q4FY25 at 111.3% was higher than our estimated 106.4% on higher-thanexpected claims cost at 76.5% (+430bps YoY) led by higher loss ratios in the Motor and Fire segments. Total expense ratio at 34.8% (-180bps YoY) beat our estimate of 35.9%.

#### Management confident of delivering a 'better than peers' performance

The management highlighted that Go Digit's performance in FY25 was better than that of most peers, and there was a marked improvement in profitability and the 'Expense of Management (EoM)' ratios. Looking ahead, the management remains confident of delivering better than industry growth with sustained improvement in economic profitability. With the pricing environment in group health still unfavorable, the company is pinning hopes on better pricing in commercial lines and a likely Motor TP Tariff hike in FY26 to help it deliver growth and profitability.

### Minor changes to estimates; reiterate SELL with unchanged TP of Rs250

To reflect the Q4FY25 developments and outlook, we tweak our FY26-27 estimates which results in broadly unchanged combined ratio and increase of ~3-8% in FY26E/27E PAT. We reiterate SELL on the stock with unchanged Mar-26E TP of Rs250. Amid an unsupportive external environment (no Motor TP Tariff hike, falling bond yields, EoM deadline aggravating the price war in Group Health, etc), we see the company's selective and opportunistic growth strategy having limitations in delivering superior growth and profitability and, hence, the premium valuation is unwarranted.

| Target Price – 12M    | Mar-26 |
|-----------------------|--------|
| Change in TP (%)      | -      |
| Current Reco.         | SELL   |
| Previous Reco.        | SELL   |
| Upside/(Downside) (%) | (19.1) |

| Stock Data              | GODIGIT IN |
|-------------------------|------------|
| 52-week High (Rs)       | 408        |
| 52-week Low (Rs)        | 265        |
| Shares outstanding (mn) | 923.0      |
| Market-cap (Rs bn)      | 285        |
| Market-cap (USD mn)     | 3,356      |
| Net-debt, FY26E (Rs mn) | NA         |
| ADTV-3M (mn shares)     | 2          |
| ADTV-3M (Rs mn)         | 345.4      |
| ADTV-3M (USD mn)        | 4.1        |
| Free float (%)          | 22.2       |
| Nifty-50                | 24,328.5   |
| INR/USD                 | 85.0       |
| Shareholding, Mar-25    |            |
| Promoters (%)           | 73.1       |
| FPIs/MFs (%)            | 7.9/15.3   |

| Price Performance |     |       |     |  |  |  |  |  |
|-------------------|-----|-------|-----|--|--|--|--|--|
| (%)               | 1M  | 3M    | 12M |  |  |  |  |  |
| Absolute          | 6.9 | 4.9   | 0.0 |  |  |  |  |  |
| Rel. to Nifty     | 3.3 | (1.0) | 0.0 |  |  |  |  |  |



| Go Digit: Financial Snapshot (Standalone) |        |         |         |         |         |  |  |  |  |
|---|--------|---------|---------|---------|---------|--|--|--|--|
| Y/E March (Rs mn)                         | FY24   | FY25    | FY26E   | FY27E   | FY28E   |  |  |  |  |
| Gross written premium                     | 90,156 | 102,821 | 119,201 | 137,339 | 158,629 |  |  |  |  |
| Net earned premium                        | 70,964 | 80,460  | 94,327  | 109,522 | 126,889 |  |  |  |  |
| Adj. PAT                                  | 1,817  | 4,249   | 6,075   | 6,716   | 8,769   |  |  |  |  |
| Adj. EPS (Rs)                             | 2.1    | 4.6     | 6.6     | 7.3     | 9.5     |  |  |  |  |
| BVPS (INR)                                | 29.1   | 44.0    | 50.0    | 56.2    | 64.2    |  |  |  |  |
| Adj. EPS growth (%)                       | 407.3  | 123.1   | 41.8    | 10.6    | 30.6    |  |  |  |  |
| BVPS growth (%)                           | 8.1    | 51.4    | 13.4    | 12.4    | 14.4    |  |  |  |  |
| NEP growth (%)                            | 37.4   | 13.4    | 17.2    | 16.1    | 15.9    |  |  |  |  |
| Combined ratio (%)                        | 108.7  | 109.3   | 106.5   | 105.5   | 104.5   |  |  |  |  |
| RoE (%)                                   | 7.4    | 12.7    | 13.9    | 13.7    | 15.8    |  |  |  |  |
| P/Float (x)                               | 1.8    | 1.5     | 1.3     | 1.1     | 1.0     |  |  |  |  |
| P/E (x)                                   | 148.6  | 66.6    | 47.0    | 42.5    | 32.5    |  |  |  |  |
| P/B (x)                                   | 10.6   | 7.0     | 6.2     | 5.5     | 4.8     |  |  |  |  |
| Caurage Company Embay Bases               | wah    |         |         |         |         |  |  |  |  |

Source: Company, Emkay Research

Avinash Singh avinash.singh@emkayglobal.com +91-22-66121327

Mahek Shah mahek.shah@emkayglobal.com +91-22-66121218

Exhibit 1: Q4FY25 / FY25 Financial Performance

| Income Statement (Rs mn)               | 4QFY25   | 4QFY24 | %YoY    | 4QFY25E  | %Var  | 3QFY25   | %QoQ    | FY25    | FY24   | YoY (%) |
|--|----------|--------|---------|----------|-------|----------|---------|---------|--------|---------|
| Gross direct premium                   | 19,810   | 19,706 | 0.5     | 20,725   | -4.4  | 21,146   | -6.3    | 84,722  | 79,411 | 6.7     |
| Gross written premium                  | 25,764   | 23,359 | 10.3    | 25,764   | -0.0  | 26,768   | -3.8    | 102,821 | 90,156 | 14.0    |
| Net written premium                    | 20,338   | 20,995 | -3.1    | 23,217   | -12.4 | 22,424   | -9.3    | 82,308  | 77,309 | 6.5     |
| Net Earned premium                     | 22,469   | 19,818 | 13.4    | 20,649   | 8.8   | 20,841   | 7.8     | 80,460  | 70,964 | 13.4    |
| Total expense                          | 24,261   | 21,982 | 10.4    | 22,903   | 5.9   | 23,089   | 5.1     | 88,650  | 79,585 | 11.4    |
| Underwriting result                    | -1,792.5 | -2,164 | -17.2   | -2,255.0 | -20.5 | -2,247.5 | -20.2   | -8,190  | -8,621 | -5.0    |
| Investment PH account                  | 2,840.6  | 7,107  | -60.0   | 2,761.0  | 2.9   | 2,876.5  | -1.2    | 11,091  | 8,788  | 26.2    |
| Operating profit                       | 1,048    | 4,943  | NM      | 506      | 107.1 | 629      | 66.6    | 2,901   | 166    | NM      |
| Net results from shareholders' account | 108      | -4,416 | -102.4  | 581      | -81.4 | 556      | -80.6   | 1,348   | 1,650  | -18.3   |
| Profit before tax                      | 1,156    | 527    | 119.1   | 1,087    | 6.4   | 1,185    | -2.5    | 4,249   | 1,817  | NM      |
| Profit after Tax                       | 1,156    | 528    | 119.0   | 1,087    | 6.4   | 1,185    | -2.5    | 4,249   | 1,817  | NM      |
| Key ratio (%)                          | 4QFY25   | 4QFY24 | ppt YoY | 4QFY25E  | Var   | 3QFY25   | ppt QoQ | FY25    | FY24   | ppt YoY |
| Claims ratio                           | 76.5     | 72.2   | 4.3     | 70.5     | 6.0   | 72.9     | 3.6     | 72.8    | 70.3   | 2.5     |
| Commission ratio                       | 29.4     | 23.8   | 5.6     | 24.4     | 5.0   | 24.2     | 5.2     | 27.1    | 24.4   | 2.6     |
| OpEx ratio                             | 5.3      | 12.8   | -7.5    | 11.5     | -6.2  | 11.0     | -5.6    | 9.4     | 14.0   | -4.5    |
| Combined ratio                         | 111.3    | 108.8  | 2.4     | 106.4    | 4.8   | 108.1    | 3.2     | 109.3   | 108.7  | 0.6     |
| RoE                                    | 10.9     | 7.9    | 3.0     | 10.2     | 0.7   | 11.4     | -0.4    | 12.7    | 7.4    | 5.3     |
| Retention ratio                        | 78.9     | 89.9   | -10.9   | 90.1     | -11.2 | 83.8     | -4.8    | 80.0    | 85.8   | -5.7    |
| Solvency ratio                         | 224.0    | 161.0  | 63.0    |          |       | 222.0    | 2.0     | 229.8   | 161.2  | 68.5    |
| Investment leverage (x)                | 4.7      | 5.9    | -1.2    |          |       | 4.7      | 0.0     | 4.7     | 5.9    | -1.2    |

Source: Company, Emkay Research

Exhibit 2: GODIGIT - Economic value-added method valuation

| Parameter (Rs mn)                             | Value   |
|---|---------|
| Cost of Equity                                | 12.0%   |
| FY25-30E Earnings CAGR                        | 25%     |
| FY30-39E Earnings CAGR                        | 15%     |
| Terminal growth                               | 8.0%    |
| FY26E Net worth (Rs mn)                       | 46,121  |
| FY27-39E discounted residual earnings (Rs mn) | 48,249  |
| Terminal Value (Rs mn)                        | 131,496 |
| FY26E Fair value gains - post tax (Rs mn)     | 1,569   |
| Fair Value (Rs mn)                            | 227,435 |
| No of shares (mn)                             | 923     |
| Mar-26E Fair value per share (Rs)             | 246     |
| Mar-26E Target price (Rs)                     | 250     |

Source: Company, Emkay Research

Exhibit 3: GODIGIT - Implied valuation multiples

| Valuation multiple at current price | Rs309 |
|-------------------------------------|-------|
| FY27E P/E                           | 42.5x |
| FY27E P/B                           | 5.5x  |
| FY27E RoE                           | 13.7% |
|                                     |       |
| Valuation multiple at target price  | Rs250 |
| FY27E P/E                           | 34.4x |
| FY27E P/B                           | 4.4x  |
| FY27E RoE                           | 13.7% |


Source: Company, Emkay Research

Exhibit 4: Changes in estimates

| (Rs mn)            | FY26E   |         |          | FY27E   |         |          |     | FY28E   |         |
|--------------------|---------|---------|----------|---------|---------|----------|-----|---------|---------|
|                    | Old     | Revised | %Change  | Old     | Revised | %Change  | Old | Revised | %Change |
| GWP                | 119,201 | 119,201 | 0.0      | 137,339 | 137,339 | 0.0      | NA  | 158,629 | NA      |
| U/W Result         | -9,014  | -7,839  | -13.0    | -9,041  | -7,991  | -11.6    | NA  | -7,946  | NA      |
| Op Profit          | 4,014   | 4,962   | 23.6     | 5,833   | 6,462   | 10.8     | NA  | 8,696   | NA      |
| PAT                | 5,640   | 6,075   | 7.7      | 6,501   | 6,716   | 3.3      | NA  | 8,769   | NA      |
| Combined Ratio (%) | 106.8   | 106.5   | -0.3ppts | 105.6   | 105.5   | -0.1ppts | NA  | 104.5   | NA      |
| RoE (%)            | 12.9    | 13.9    | 1.0ppts  | 13.0    | 13.7    | 0.7ppts  | NA  | 15.8    | NA      |


# **Story in charts**

Exhibit 5: GDPI growth slows down sequentially and YoY




Source: Company, Emkay Research

Exhibit 7: Combined Ratio elevates to 111.3% in Q4FY25




Source: Company, Emkay Research

Exhibit 9: Go Digit's PAT grows to Rs1.16bn in Q4FY25




Source: Company, Emkay Research

**Exhibit 6: Motor TP continues to be the largest segment** 



Source: Company, Emkay Research

Exhibit 8: Go Digit reports PBT of Rs1.2bn in Q4FY25



Source: Company, Emkay Research

Exhibit 10: Investment leverage remains broadly stable






Exhibit 11: We expect Go Digit's GDPI to grow 12-13% over FY26-28E




Source: Company, Emkay Research

Exhibit 13: We expect Go Digit's PBT to improve to Rs12bn in FY28E




Source: Company, Emkay Research

Exhibit 12: CoR is expected to improve gradually over FY26-28E



Source: Company, Emkay Research

Exhibit 14: Go Digit's PAT is expected to grow to Rs8.8bn by FY28E



# **Earnings Conference Call Highlights**

- The management mentioned that the company is focusing on businesses with lower commission. However, these businesses might have slightly higher loss ratios, but will be beneficial from an RoE perspective.
- In FY25, no capital gains were booked; in fact, there was some capital loss on account of an increase in the duration of fixed income portfolio.
- The company will allocate up to 10% of Assets in Equity. The management mentioned that the company got an opportunity in February when the equity markets were weak and, hence, the Equity allocation has increased to ~6%.
- The company has seen good development in health segment growth and loss ratios. Health Loss ratio at an overall level is quite competitive compared with peers. The management mentioned that Go Digit is rightly positioned despite its small size in the health segment, and would increase this business substantially when an opportunity arises.
- The company has been able to increase reinsurance capacities and achieved better rates.
- The trend in Q4FY25 can give some indication on growth in the Motor OD business. In April, it seems Motor OD growth has been decent for the company.
- On Group Medical Coverage, April saw high competition as big renewals were due in the month. But with smaller renewals, there has been some improvement in pricing. If there is slight correction in the GMC market, the company will be able to increase the share of the business.
- Reserve release in Q2 was 37% of NEP. This year, the TP loss reserve release impact is 5.3% of the total loss ratio.
- The management focuses more on GWP and not GDPI. In some lines of business, the company would prefer to write on a direct basis or on reinsurance acceptance basis. The management expects the company's GWP growth to be higher than growth for the industry.
- There was some unexpected competition in Fire. This year, Fire prices have improved, and the real impact will be seen July onward. The management expects some increase in Motor TP premium rates. Assuming stable economic growth, the management expects the industry growth rate to be 3-4% higher vs previous year.
- In the Motor OD business, Cars would be  $\sim$ 42% of the business while 2Ws and CVs would be 30-30% each. The 2W business would entail more of new vehicles. In PVs, the mix will start moving toward old vehicles as the renewal book starts growing faster.
- PVs have the lowest OD loss ratio, while CVs have higher loss ratios in Motor OD and Motor TV.
- The management expects good growth in Commercial Lines. Having also increased the treaty capacities, the management expects better growth in the commercial business which does not only include the fire segment. Further, the company has been moving its product mix more toward the Non-Motor side.
- Overall, reduction in expense ratios was seen in Q4FY25. Further, the management mentioned that there has been some reduction in the Commission-to-GWP ratio.
- Without 1/n basis, the Expense-to-GWP ratio has reduced to ~33.4% and, with 1/n basis, it is 33.9%. There are likely to be only 4-5 companies that would have reduced the EoM during the year. And the company reducing the EoM by ~3% over FY25 would be faring considerably well.
- IRDAI's objective, with the EoM guidelines, was to reduce commissions. But in actuality, commissions have gone up. The management expects the IRDAI to take some corrective actions related to EoM.
- A number of other players would have seen increase in EoM and, in this context, Go Digit is in a better position.

## **Go Digit: Standalone Financials and Valuations**

| Profit & Loss           |         |         |         |         |         |
|-------------------------|---------|---------|---------|---------|---------|
| Y/E March (Rs mn)       | FY24    | FY25    | FY26E   | FY27E   | FY28E   |
| GDPI                    | 79,411  | 84,722  | 94,581  | 105,896 | 120,161 |
| Gross written premium   | 90,156  | 102,821 | 119,201 | 137,339 | 158,629 |
| Net written premium     | 77,309  | 82,308  | 99,410  | 115,416 | 133,595 |
| Net earned premium      | 70,964  | 80,460  | 94,327  | 109,522 | 126,889 |
| Net incurred claims     | 49,902  | 58,590  | 68,191  | 78,718  | 90,366  |
| Net commission          | 18,885  | 22,284  | 24,186  | 27,429  | 31,313  |
| Operating expense       | 10,799  | 7,776   | 9,790   | 11,366  | 13,156  |
| Total expense           | 79,585  | 88,650  | 102,166 | 117,513 | 134,836 |
| Underwriting profit     | (8,621) | (8,190) | (7,839) | (7,991) | (7,946) |
| Investment income       | 8,788   | 11,091  | 12,801  | 14,453  | 16,642  |
| Other income            | 4,676   | 3,245   | 0       | 0       | 0       |
| Operating profit        | 4,842   | 6,146   | 4,962   | 6,462   | 8,696   |
| Shareholder results     | (3,025) | (1,896) | 2,181   | 2,577   | 3,106   |
| PBT                     | 1,817   | 4,249   | 7,143   | 9,039   | 11,802  |
| Tax expense             | 0       | 0       | 1,068   | 2,323   | 3,033   |
| Reported PAT            | 1,817   | 4,249   | 6,075   | 6,716   | 8,769   |
| PAT growth (%)          | -       | -       | -       | -       | -       |
| Adjusted PAT            | 1,817   | 4,249   | 6,075   | 6,716   | 8,769   |
| Diluted EPS (Rs)        | 2.1     | 4.6     | 6.5     | 7.2     | 9.4     |
| Diluted EPS growth (%)  | 412.5   | 123.1   | 41.8    | 10.6    | 30.6    |
| DPS (Rs)                | 0       | 0       | 0.7     | 1.1     | 1.4     |
| Dividend payout (%)     | 0       | 0       | 10.0    | 15.0    | 15.0    |
| Effective tax rate (%)  | 0       | 0       | 15      | 26      | 26      |
| Shares outstanding (mn) | 875.2   | 923.0   | 923.0   | 923.0   | 923.0   |

Source: Company, Emkay Research

| <b>Balance Sheet</b>       |           |           |           |           |           |
|----------------------------|-----------|-----------|-----------|-----------|-----------|
| Y/E March (Rs mn)          | FY24      | FY25      | FY26E     | FY27E     | FY28E     |
| Share capital              | 8,752     | 9,230     | 9,230     | 9,230     | 9,230     |
| Reserves & Surplus         | 23,951    | 34,411    | 36,891    | 42,600    | 50,053    |
| Net worth                  | 32,703    | 43,641    | 46,121    | 51,830    | 59,283    |
| Fair value gains           | 1,729     | 2,483     | 2,092     | 2,301     | 2,531     |
| Borrowings                 | 3,500     | 3,500     | 3,500     | 3,500     | 3,500     |
| Total liabilities & equity | 37,932    | 49,624    | 51,713    | 57,631    | 65,315    |
| Policyholder investments   | 133,694   | 155,277   | 175,088   | 205,286   | 235,607   |
| Shareholder Investments    | 20,383    | 39,363    | 44,385    | 52,040    | 59,726    |
| Other assets               | 1,628     | 1,616     | 1,696     | 1,781     | 1,870     |
| Cash & bank balances       | 3,561     | 2,391     | 3,926     | 4,122     | 4,328     |
| Other current assets       | 10,320    | 15,963    | 28,475    | 40,652    | 48,207    |
| Claims outstanding         | 72,752    | 92,158    | 110,749   | 135,106   | 156,050   |
| Unearned premium           | 36,873    | 38,776    | 46,598    | 56,846    | 65,658    |
| Other current liab.        | 29,116    | 36,882    | 44,322    | 54,070    | 62,452    |
| Provisions                 | 37,022    | 38,932    | 46,785    | 57,075    | 65,922    |
| Net current assets         | (125,009) | (149,619) | (169,455) | (201,476) | (231,889) |
| Total assets               | 37,932    | 49,624    | 51,713    | 57,631    | 65,315    |
| BVPS (Rs)                  | 29.1      | 44.0      | 50.0      | 56.2      | 64.2      |
| Investment leverage (x)    | 5.9       | 4.7       | 4.7       | 4.9       | 4.9       |
| Net investment yield (%)   | 7.6       | 7.6       | 7.6       | 7.5       | 7.4       |
| PH investment yield (%)    | 7.5       | 7.7       | 7.7       | 7.6       | 7.5       |
| SH investment yield (%)    | 8.2       | 7.2       | 7.0       | 6.9       | 6.9       |
| NWP/Networth (x)           | 2.8       | 1.9       | 2.1       | 2.1       | 2.2       |
| Required Solvency [RSM]    | 17,589    | 19,033    | 22,616    | 26,049    | 30,241    |
| Available Solvency [ASM]   | 28,361    | 43,734    | 49,202    | 54,910    | 62,363    |

Source: Company, Emkay Research

| Miscellaneous Metrics |       |       |       |       |       |  |  |  |
|-----------------------|-------|-------|-------|-------|-------|--|--|--|
| Y/E Mar (Rs mn)       | FY24  | FY25  | FY26E | FY27E | FY28E |  |  |  |
| Operating metrics (%) |       |       |       |       |       |  |  |  |
| Retention ratio       | 85.8  | 80.0  | 83.4  | 84.0  | 84.2  |  |  |  |
| Incurred claims ratio | 70.3  | 72.8  | 72.3  | 71.9  | 71.2  |  |  |  |
| Net commission ratio  | 24.4  | 27.1  | 24.3  | 23.8  | 23.4  |  |  |  |
| Opex ratio            | 14.0  | 9.4   | 9.8   | 9.8   | 9.8   |  |  |  |
| Combined ratio        | 108.7 | 109.3 | 106.5 | 105.5 | 104.5 |  |  |  |
| RSM-to-NWP            | 22.8  | 23.1  | 22.7  | 22.6  | 22.6  |  |  |  |
| Solvency ratio        | 161.2 | 224.0 | 217.6 | 210.8 | 206.2 |  |  |  |
|                       |       |       |       |       |       |  |  |  |
| Claims ratio (%)      |       |       |       |       |       |  |  |  |
| Motor TP              | 60.5  | 65.5  | 68.0  | 66.5  | 65.0  |  |  |  |
| Motor OD              | 66.1  | 66.0  | 66.0  | 68.0  | 67.0  |  |  |  |
| Health                | 98.4  | 86.5  | 86.0  | 84.0  | 84.0  |  |  |  |
| Fire                  | 85.7  | 65.0  | 63.0  | 60.0  | 60.0  |  |  |  |
| Crop                  | 93.0  | 90.0  | 95.0  | 95.0  | 95.0  |  |  |  |
| Others                | 50.4  | 58.2  | 51.4  | 51.1  | 51.0  |  |  |  |
| GWP mix (%)           |       |       |       |       |       |  |  |  |
| Motor TP              | 39.0  | 35.2  | 32.5  | 30.4  | 28.5  |  |  |  |
| Motor OD              | 21.7  | 22.3  | 23.1  | 24.0  | 24.9  |  |  |  |
| Health                | 15.9  | 17.5  | 18.8  | 19.6  | 20.4  |  |  |  |
| Fire                  | 8.9   | 8.1   | 8.0   | 7.8   | 7.6   |  |  |  |
| Crop                  | 6.0   | 6.8   | 6.8   | 6.8   | 6.7   |  |  |  |
| Others                | 8.4   | 10.1  | 10.8  | 11.3  | 11.9  |  |  |  |
| Total                 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 |  |  |  |

Source: Company, Emkay Research

| Y/E March             | FY24  | FY25  | FY26E  | FY27E | FY28E |
|-----------------------|-------|-------|--------|-------|-------|
| P/B (x)               | 10.6  | 7.0   | 6.2    | 5.5   | 4.8   |
| P/E (x)               | 148.6 | 66.6  | 47.0   | 42.5  | 32.5  |
| P/Float (x)           | 1.8   | 1.5   | 1.3    | 1.1   | 1.0   |
| P/GWP (x)             | 3.0   | 2.8   | 2.4    | 2.1   | 1.8   |
| Dividend yield (%)    | 0     | 0     | 0.2    | 0.4   | 0.5   |
| Dupont-RoE split (%)  |       |       |        |       |       |
| NEP/avg assets        | 51.1  | 46.1  | 45.6   | 45.9  | 45.9  |
| Net incurred claims   | 35.9  | 33.6  | 32.9   | 33.0  | 32.7  |
| Commission + Opex     | 21.4  | 17.2  | 16.4   | 16.3  | 16.1  |
| Underwriting profit   | (6.2) | (4.7) | (3.8)  | (3.4) | (2.9) |
| PH investment income  | 6.3   | 6.4   | 6.2    | 6.1   | 6.0   |
| Operating profit      | 3.5   | 3.5   | 2.4    | 2.7   | 3.1   |
| Shareholder results   | (2.2) | (1.1) | 1.1    | 1.1   | 1.1   |
| Tax expense           | 0     | 0     | 0.5    | 1.0   | 1.1   |
| RoA                   | 1.3   | 2.4   | 2.9    | 2.8   | 3.2   |
| Leverage ratio (x)    | 5.9   | 4.7   | 4.7    | 4.9   | 4.9   |
| RoE                   | 7.4   | 12.7  | 13.9   | 13.7  | 15.8  |
| Growth rates (%)      |       |       |        |       |       |
| GDPI                  | 28.9  | 6.7   | 11.6   | 12.0  | 13.5  |
| Gross written premium | 24.5  | 14.0  | 15.9   | 15.2  | 15.5  |
| Net written premium   | 30.8  | 6.5   | 20.8   | 16.1  | 15.8  |
| Net earned premium    | 37.4  | 13.4  | 17.2   | 16.1  | 15.9  |
| Claims incurred       | 43.8  | 17.4  | 16.4   | 15.4  | 14.8  |
| Operating profit      | 20.7  | 26.9  | (19.3) | 30.2  | 34.6  |

### **RECOMMENDATION HISTORY - DETAILS**

| Date      | Closing<br>Price (INR) | TP (INR) | Rating | Analyst       |
|-----------|------------------------|----------|--------|---------------|
| 20-Apr-25 | 298                    | 250      | Sell   | Avinash Singh |
| 03-Apr-25 | 287                    | 250      | Sell   | Avinash Singh |
| 18-Feb-25 | 301                    | 250      | Sell   | Avinash Singh |
| 23-Jan-25 | 327                    | 250      | Sell   | Avinash Singh |
| 19-Jan-25 | 291                    | 240      | Sell   | Avinash Singh |
| 27-Oct-24 | 320                    | 240      | Sell   | Avinash Singh |
| 17-Oct-24 | 361                    | 240      | Sell   | Avinash Singh |
| 04-Oct-24 | 378                    | 240      | Sell   | Avinash Singh |
| 01-Sep-24 | 384                    | 230      | Sell   | Avinash Singh |
| 27-Jul-24 | 346                    | 230      | Sell   | Avinash Singh |
| 23-Jul-24 | 339                    | 210      | Sell   | Avinash Singh |
| 18-Jun-24 | 334                    | 210      | Sell   | Avinash Singh |
| 24-May-24 | 300                    | 210      | Sell   | Avinash Singh |

Source: Company, Emkay Research

### **RECOMMENDATION HISTORY - TREND**



Source: Company, Bloomberg, Emkay Research

### GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of BSE Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX), Multi Commodity Exchange of India Ltd (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) (hereinafter referred to be as "Stock Exchange(s)"). EGFSL along with its [affiliates] offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayglobal.com.

EGFSL is registered as Research Analyst with the Securities and Exchange Board of India ("SEBI") bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any Stock Exchange nor its activities were suspended by any Stock Exchange with whom it is registered in last five years. However, SEBI and Stock Exchanges had conducted their routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to its existing clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was. is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the clients simultaneously, not all clients may receive this report at the same time. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. EGFSL may have issued or may issue other reports (on technical or fundamental analysis basis) of the same subject company that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Users of this report may visit www.emkayglobal.com to view all Research Reports of EGFSL. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of EGFSL; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL . All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its affiliates. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

This report has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research report relating to any issuer/subject company.

Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets.

Disclaimer for U.S. persons only: Research report is a product of Emkay Global Financial Services Ltd., under Marco Polo Securities 15a6 chaperone service, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors. Emkay Global Financial Services Ltd. has entered into a chaperoning agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

#### RESTRICTIONS ON DISTRIBUTION

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. Except otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom.

#### ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associated persons1 may have served as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate may have Financial Interests2 in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

<sup>1</sup> An associated person is defined as (i) who reports directly or indirectly to such a research analyst in connection with the preparation of the reports; or (ii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

#### COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report-:

- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her associate/relative's may have Financial Interest/proprietary positions in the securities recommended in this report as of April 29, 2025
- EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Report

#### Disclosure of previous investment recommendation produced:

- 3. EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's may have material conflict of interest in the securities recommended in this report as of April 29, 2025
- EGFSL, its affiliates and Research Analyst or his/her associate/relative's may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the April 29, 2025
- EGFSL or its associates may have managed or co-managed public offering of securities for the subject company in the past twelve months.
- EGFSL, its affiliates and Research Analyst or his/her associate may have received compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- EGFSL, its affiliates and/or and Research Analyst or his/her associate may have received any compensation or other benefits from the subject company or third party in connection with this research report.

### **Emkay Rating Distribution**

| Ratings | Expected Return within the next 12-18 months. |  |  |
|---------|---|--|--|
| BUY     | >15% upside                                   |  |  |
| ADD     | 5-15% upside                                  |  |  |
| REDUCE  | 5% upside to 15% downside                     |  |  |
| SELL    | <15% downside                                 |  |  |

#### **Emkay Global Financial Services Ltd.**

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marq, Dadar - West, Mumbai - 400028. India Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com

<sup>&</sup>lt;sup>2</sup> Financial Interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

#### OTHER DISCLAIMERS AND DISCLOSURES:

Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) -:

EGFSL or its associates may have financial interest in the subject company.

Research Analyst or his/her associate/relative's may have financial interest in the subject company.

EGFSL or its associates and Research Analyst or his/her associate/ relative's may have material conflict of interest in the subject company. The research Analyst or research entity (EGFSL) have not been engaged in market making activity for the subject company.

EGFSL or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst or his/her associate/relatives may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst may have served as an officer, director or employee of the subject company.

EGFSL or its affiliates may have received any compensation including for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. . Emkay may have issued or may issue other reports that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Emkay Investors may visit www.emkayglobal.com to view all Research Reports. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of Emkay; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. EGFSL or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EGFSL or its associates may have received any compensation or other benefits from the Subject Company or third party in connection with the research report. EGFSL or its associates may have received compensation from the subject company in the past twelve months. Subject Company may have been client of EGFSL or its affiliates during twelve months preceding the date of distribution of the research report and EGFSL or its affiliates may have co-managed public offering of securities for the subject company in the past twelve months.

Kumar Sen Date: 2025.04.29 05:04:08 +05'30'

Seshadri Digitally signed by Seshadri Kumar Sen